Lilly's obesity drug crushes Ozempic in trials — long LLY and steer clear of restaurants into Chipotle earnings

Verdict: right thesis, wrong day — wait for the trigger, not the headline

Our stance over the next three months is cautious agreement with the idea's direction but a clear wait on execution. The strongest support for the trade is Lilly's demand story: Q2 revenue jumped 16.0% quarter over quarter to $23.0B with operating cash flow doubling to $10.7B, while Chipotle's own numbers show the pressure case has some footing — CMG still printed $3.35B in Q2 revenue, up 8.4%, with net income up 33.3% to $403.5M, so the bearish case rests on slowing growth, not a collapsing business. The strongest objection is that Chipotle is a healthy, buyback-enabled company shrinking its share count 1.4% in a quarter, and the bearish positioning into an unconfirmed earnings date is a crowded trade; on the long side, Lilly insiders were net open-market sellers of roughly $2.9M in provisional ownership filings through September 30, 2026, and its net margin fell 6.5 points to 30.9% even as revenue grew. Neither leg's entry conditions are live: CMG closed at $29.06, six cents above the required $29.00 break, with momentum 1.2 points short, and Lilly sits near its range high with momentum far from a pullback entry. No backtest supports the rule set either, because Lilly's raw and adjusted price series could not be reconciled, so this rests on fundamentals and filings alone. A confirmed CMG close below $29.00 alongside a weak comparable-sales guide, or a reversal in Lilly's insider selling and margin trend, would change the call.

Trade now

The research thesis is coherent, but the entry conditions are not met today, so the actionable answer is **wait**. The idea argues that Eli Lilly's trial win sharpens a demand headwind for restaurants — with Chipotle (CMG) the cautious side and Lilly (LLY) the beneficiary. The business logic lines up with the numbers: CMG's latest quarter (ended June 30, 2026) grew revenue 8.4% quarter over quarter to $3.35B, yet the stock's annualized return over two years of data is -38.0% with a 58.4% peak-to-trough decline, while LLY grew revenue 16.0% to $23.0B and has compounded at +18.3% annualized. The direction of the thesis looks right; the timing does not. The horizon is unspecified in the idea, and Chipotle's next earnings date is not confirmed in the supplied data. What "wait" means concretely. The frozen rule set requires, for the CMG short leg: a daily close below the first support level (currently $29.00, versus a last close of $29.06), the 20-day moving average below the 50-day (already met), on-balance volume below zero (the value is unavailable, so this cannot be verified), and a 14-day RSI — a 0–100 momentum reading — at or below 45 (currently 46.2, close but not there). The LLY long leg is even further away: its RSI is 68.3, well above the required 45, and its 20-day average sits above its 50-day — momentum is currently running against a pullback entry. No condition set is live for either leg. One scope note: the historical performance of this rule set was never measured, because Lilly's raw and adjusted price series could not be reconciled on a common basis. No backtest result therefore supports or refutes the entry rules, and no robust parameter setup was established for the same reason. The downside risk to the bearish CMG read is a strong earnings print or a rebound off the $29.00 support — the stock is already 28.9% below its range high, so much of the pessimism may be priced in. On the long side, LLY insiders were net open-market sellers (about -$2.9M in provisional data through September 30, 2026), a caution against chasing the drugmaker at $1,298. ### Technical details Observations are as of October 28, 2026 (daily bars). **CMG** last close $29.06; the 20-day EMA of $29.92 sits below the 50-day EMA of $31.51 (trend rule met); RSI (14) of 46.2 versus a required reading at or below 45 (1.2 points away); on-balance volume is unavailable, so the below-zero condition cannot be confirmed; entry requires a close below the first support at $29.00 — the close is currently $0.06 above that trigger. Second support sits at $28.03, the designated downside exit level. **LLY** last close $1,298, just 0.7% below its range high of roughly $1,307; the 20-day EMA of $1,238.60 is above the 50-day EMA of $1,202.50 (trend rule not met, about $36.20 apart); RSI (14) of 68.3, 23.3 points above the required 45; entry would need a close below the first support at $1,200. Exits in the rule set: an RSI reading above 65 after a holding period of 45 or more bars signals an exit — LLY's RSI already exceeds 65; a cross below the first support acts as a stop; a hard stop sits at -2.0% unrealized and take-profit at +4.0%, with a 25% maximum position size under a fixed 2%-risk sizing method. Correlation between the two names over the 730-day lookback is 0.06 — nearly uncorrelated, so the legs do not hedge each other mechanically.

The GLP-1 demand story has two willing sides — and Lilly's numbers are the stronger half

The bearish-restaurant, long-Lilly framing is supported by Lilly's accelerating growth and a second quarter that showed no sign of GLP-1 demand stalling, while Chipotle's own reported numbers show softening momentum. One scope note up front: the historical performance of this idea's rule set was not measured because Lilly's raw and adjusted price series use different bases, so no backtest evidence exists for either direction — the judgment below rests on fundamentals and filings only. ### Lilly's growth is real and accelerating Per the Reuters report on the trial, Lilly's next-generation drug beat Ozempic on both weight loss and blood sugar control — a competitive outcome that should extend the company's franchise rather than threaten it. The reported financials back the demand: Q2 2026 revenue rose to $23.0B from $19.8B the prior quarter, a 16.0% sequential jump, following 42.5% year-over-year revenue growth in the latest full-year quarter that placed Lilly around the 76th percentile among 1,042 health-care peers. Growth of this scale is the engine the long-Lilly leg depends on. ### Lilly's cash machine is strengthening Operating cash flow doubled quarter over quarter to $10.7B from $5.3B, and net margin held above 30% at 30.9% despite the sequential dip from 37.4%. Gross margin also expanded to 85.8% from 81.9%. For a company funding large-scale manufacturing and trials, that cash generation is what converts a drug win into earnings power rather than just headlines. ### Chipotle's momentum is fading, not collapsing Chipotle's Q2 2026 shows the cautious-restaurant case has some factual footing: revenue growth was only 8.4% sequentially to $3.3B, and the latest full-year quarter's year-over-year growth of 4.9% sat near the median of consumer-discretionary peers — hardly the growth profile that usually supports a premium restaurant multiple. Operating margin fell year over year from the mid-16% range to 14.1%, and full-year 2025 free cash flow of $1.4B was down from $1.5B in 2024. If diners genuinely eat out less, these are the lines that bend first. ### Sentiment positioning matches the demand thesis Per CNBC's report, traders are betting heavily against…

Scores

• Conviction score breakdown: 48
• Thesis support: 62
• Trade readiness: 28
• Risk quality: 45
• Fundamentals trend: 55

Watch items

• CMG — RSI (14)
• CMG — Daily close vs. first support
• LLY — RSI (14)
• LLY — Daily close vs. first support